Skip to main content
Top
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Commentary

Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside

Authors: Rickey E Carter, Robert F Woolson

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

Pilot studies are often used to transition therapies developed using animal models to a clinical setting. Frequently, the focus of such trials is on estimating the safety in terms of the occurrence of certain adverse events. With relatively small sample sizes, the probability of observing even relatively common events is low; however, inference on the true underlying event rate is still necessary even when no events of interest are observed. The exact upper limit to the event rate is derived and illustrated graphically. In addition, the simple algebraic expression for the confidence bound is seen to be useful in the context of planning studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Spilker B: Guide to Clinical Trials. 1991, Raven Press Spilker B: Guide to Clinical Trials. 1991, Raven Press
2.
go back to reference Friedman LM, Furberg C, DeMets DL: Fundamentals of Clinical Trials. 1998, Springer-Verlag IncCrossRef Friedman LM, Furberg C, DeMets DL: Fundamentals of Clinical Trials. 1998, Springer-Verlag IncCrossRef
3.
go back to reference Schoenfeld D: Statistical considerations for pilot studies. International Journal of Radiation Oncology, Biology, Physics. 1980, 6 (3): 371-374.CrossRefPubMed Schoenfeld D: Statistical considerations for pilot studies. International Journal of Radiation Oncology, Biology, Physics. 1980, 6 (3): 371-374.CrossRefPubMed
4.
go back to reference Shih WJ, Ohman-Strickland PA, Lin Y: Analysis of pilot and early phase studies with small sample sizes. Statistics in Medicine. 2004, 23: 1827-1842. 10.1002/sim.1807.CrossRefPubMed Shih WJ, Ohman-Strickland PA, Lin Y: Analysis of pilot and early phase studies with small sample sizes. Statistics in Medicine. 2004, 23: 1827-1842. 10.1002/sim.1807.CrossRefPubMed
5.
go back to reference Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934, 26: 406-413.CrossRef Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934, 26: 406-413.CrossRef
6.
go back to reference Louis TA: Confidence intervals for a binomial parameter after observing no successes. The American Statistician. 1981, 35: 154-154. Louis TA: Confidence intervals for a binomial parameter after observing no successes. The American Statistician. 1981, 35: 154-154.
7.
go back to reference Grau J, Estape J, Cuchi M, Firvida J, Blanch J, Ascaso C: Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol. 1996, 42: 233-235. 10.1046/j.1365-2125.1996.39114.x.PubMedCentralCrossRefPubMed Grau J, Estape J, Cuchi M, Firvida J, Blanch J, Ascaso C: Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol. 1996, 42: 233-235. 10.1046/j.1365-2125.1996.39114.x.PubMedCentralCrossRefPubMed
8.
go back to reference Kovach J, Moertel C, Schutt A, Reitemeier R, Hahn R: Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep. 1973, 57 (3): 357-359.PubMed Kovach J, Moertel C, Schutt A, Reitemeier R, Hahn R: Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep. 1973, 57 (3): 357-359.PubMed
9.
go back to reference Carter RE, Woolson RF: Safety Assessment in Pilot Studies When Zero Events Are Observed. Proceedings of International Conference On Statistics in Health Sciences. Carter RE, Woolson RF: Safety Assessment in Pilot Studies When Zero Events Are Observed. Proceedings of International Conference On Statistics in Health Sciences.
10.
go back to reference Winkler RL, Smith JE, Fryback DG: The Role of Informative Priors in Zero-numerator Problems: Being Conservative Versus Being Candid. The American Statistician. 2002, 56: 1-4. 10.1198/000313002753631295.CrossRef Winkler RL, Smith JE, Fryback DG: The Role of Informative Priors in Zero-numerator Problems: Being Conservative Versus Being Candid. The American Statistician. 2002, 56: 1-4. 10.1198/000313002753631295.CrossRef
11.
go back to reference Lewis JA: Post-marketing surveillance – how many patients?. Trends in Pharmacological Sciences. 1981, 2: 93-94. 10.1016/0165-6147(81)90275-3.CrossRef Lewis JA: Post-marketing surveillance – how many patients?. Trends in Pharmacological Sciences. 1981, 2: 93-94. 10.1016/0165-6147(81)90275-3.CrossRef
Metadata
Title
Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside
Authors
Rickey E Carter
Robert F Woolson
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-37

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine